Chinese company Kintor Pharmaceutical has reported that preliminary analysis data from an investigator-initiated trial (IIT) of its Proxalutamide for treating Covid-19 showed the trial met both of the co-primary efficacy endpoints.
A novel androgen receptor (AR) antagonist, Proxalutamide is currently in Phase I-III clinical trials in China and the US for treating prostate and breast cancer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Proxalutamide could limit the expression of ACE-2 and TMPRSS2, which play a major role in SARS-CoV-2 binding and entering host cells in the lungs, Kintor has found.
The randomised, double-blind and placebo-controlled clinical trial is analysing the role of the anti-androgen agent for treating Covid-19. The preliminary analysis of the trial enrolled 319 participants.
The number of patients hospitalised with Covid-19 and the Covid-19 Ordinal Outcome Scale in 30 days are the trial’s co-primary endpoints.
Data showed that in the Proxalutamide arm, the hospitalisation rate was 0.8% versus 27% in the control arm.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn the treatment arm, no mechanical ventilation usage or death was observed as compared to 9% and 2% respectively in the control arm.
Kintor Pharmaceutical founder, chairman and CEO Dr Tong Youzhi said: “Proxalutamide, as an AR antagonist, is used for the treatment of tumour and AR-related non-tumour diseases.
“We are glad to see the positive results in Covid-19 clinical trials with Proxalutamide, which is expected to reduce the probability of the progression from mild to severe in Covid-19 patients by lowering the expression of TMPRSS2 and ACE-2 proteins.”
“We are actively initiating MRCT Phase III clinical trials in countries such as the US and China, and hope to obtain an emergency use authorisation (EUA), in this way more Covid-19 patients would benefit from Proxalutamide.”
The final clinical study results from the clinical trial are expected in January next year.
